🇺🇸 FDA

Company profile · Sponsor

Legend

Legend Biotech Corp

LEGN · NYSE biotech SOMERSET, NJ, USA
Pipeline
24
Drugs
0
Patents
8

Quick answer

Legend (LEGN) is a biotech company. headquartered in SOMERSET, NJ, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker LEGN
Exchange NYSE
Company type biotech
Headquarters SOMERSET, NJ, USA
SEC CIK 0001801198

Pipeline (24)

Search pipeline →

  1. LCAR-B38M CAR-T Cell

    Legend

    Multiple Myeloma

    phase 2 mab terminated

    1 trial

  2. LCAR-B38M CAR-T cell injection

    Legend

    Refractory or Relapsed Multiple Myeloma

    phase 2 mab active

    1 trial

  3. CAR-T Re-treatment

    Legend

    Multiple Myeloma

    phase 1 small molecule active

    1 trial

  4. CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product

    Legend

    Relapsed/Refractory B-cell Malignancies

    phase 1 mab active

    1 trial

  5. Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy

    Legend

    Lymphoma, B-Cell

    phase 1 small molecule terminated

    1 trial

  6. Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy

    Legend

    Refractory B Acute Lymphoblastic Leukemia

    phase 1 small molecule terminated

    1 trial

  7. Efficacy of LCAR-T2C CAR-T cells

    Legend

    T Cell Lymphoma

    phase 1 small molecule terminated

    1 trial

  8. Efficacy of LCAR-T2C CAR-T cells

    Legend

    CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia)

    phase 1 small molecule terminated

    1 trial

  9. LB1901

    Legend

    T-Cell Lymphoma

    phase 1 mab active

    1 trial

  10. LB1908

    Legend

    Gastric Cancer

    phase 1 mab active

    1 trial

  11. LB2102

    Legend

    Small Cell Lung Cancer Extensive Stage

    phase 1 mab active

    1 trial

  12. LCAR-AIO T cells

    Legend

    Systemic Lupus Erythematosus (SLE)

    phase 1 mab active

    1 trial

  13. LCAR-AIO T cells

    Legend

    Multiple Sclerosis (MS)

    phase 1 mab active

    1 trial

  14. LCAR-AIO T cells

    Legend

    Relapsed/Refractory Autoimmune Diseases

    phase 1 mab terminated

    1 trial

  15. LCAR-AIO cells product

    Legend

    B-cell Lymphoma Recurrent

    phase 1 mab terminated

    1 trial

  16. LCAR-AMDR Cells Product

    Legend

    Acute Myeloid Leukemia

    phase 1 mab terminated

    1 trial

  17. LCAR-B4822M CAR-T Cell Immunotherapy

    Legend

    Refractory or Relapsed Multiple Myeloma

    phase 1 small molecule active

    1 trial

  18. LCAR-BCDR cells product

    Legend

    Relapsed/Refractory Multiple Myeloma

    phase 1 mab terminated

    1 trial

  19. LCAR-BCX cells product

    Legend

    Relapsed/Refractory Multiple Myeloma

    phase 1 mab active

    1 trial

  20. LCAR-C182A cells

    Legend

    Gastric Cancer

    phase 1 mab terminated

    1 trial

  21. LCAR-C18S cells

    Legend

    Solid Tumors, Adult

    phase 1 mab terminated

    1 trial

  22. LCAR-G08 cells

    Legend

    Advanced Gastrointestinal Tumors

    phase 1 mab terminated

    1 trial

  23. LCAR-HL30 cells

    Legend

    Hodgkin's Lymphoma

    phase 1 mab active

    1 trial

  24. LCAR-M23 cells

    Legend

    Epithelial Ovarian Cancer

    phase 1 mab terminated

    1 trial

Patents (8)

Search patents →

  1. US 12421292

    Anti-DLL3 chimeric antigen receptors and uses thereof

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12351638

    Chimeric antigen receptors targeting BCMA and methods of use thereof

    Expires Mon Jul 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12275788

    Single-domain antibodies against CD33 and constructs thereof

    Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12258418

    Claudin18.2 binding moieties and uses thereof

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12240914

    Antibody against factor XIa in activated form of coagulant factor XI, preparation method therefor and use thereof

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12168688

    Antibodies and variants thereof against PD-L1

    Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12097219

    Single-domain antibodies against CLL1 and constructs thereof

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12006363

    Anti-tetraspanin 33 agents and compositions and methods for making and using the same

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Legend?

Legend (LEGN) is a biotech company. headquartered in SOMERSET, NJ, USA. listed on NYSE. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Legend sponsor?

We track 24 ClinicalTrials.gov-linked programs for Legend, including LCAR-B38M CAR-T Cell and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Legend company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.